Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seay, A. R.
Right arrow Articles by Murray, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seay, A. R.
Right arrow Articles by Murray, R. S.
NEUROLOGY 1987;37:1189
© 1987 American Academy of Neurology

Interferon treatment of experimental Ross River virus polymyositis

Alan R. Seay, MD, Earl R. Kern, PhD and Ronald S. Murray, MD

Departments of Neurology and Pediatrics. Divisions of Pediatric Neurology and Infectious Diseases, University of Utah School of Medicine, Salt Lake City, UT.

Ross River virus (RRV), an alpha togavirus, causes an inflammatory myopathy in mice, which probably results from direct lytic effects of virus or viral products on myofibers. Administration of recombinant hybrid human leukocyte interferon-alpha A/D (rINF-{alpha}A/D) ameliorates clinical illness and reduces mortality from 86 to 42%. Peak concentrations of virus are reduced by 1,000-fold in serum and by 30-fold in muscle, but anti-RRV antibody production is not altered. Treatment with rIFN-{alpha}A/D dramatically reduces inflammation and necrosis in muscle. Beneficial effects of rIFN-{alpha}A/D on experimental, RRV-induced polymyositis result in part from inhibition of viral replication and spread, though immunomodulation might also play an important role.

Address correspondence and reprint requests to Dr. Seay, Division of Pediatric Neurology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425.

Supported in part by basic research grants from the Muscular Dystrophy Association of America, New York, NY, and the Fitch Foundation, Salt Lake City, UT.

Presented in part at the thirty-seventh annual meeting of the American Academy of Neurology, Dallas, TX, April 1985.

Received June 13, 1986. Accepted for publication in final form October 23, 1986.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.